氯胺酮抗抑郁效应中阿片能调节的脑血流特征:随机交叉研究
该随机双盲交叉研究纳入26名重性抑郁障碍成人,比较口服纳曲酮50 mg或安慰剂预处理后静脉氯胺酮(0.5 mg/kg,40分钟)对区域脑血流的影响。氯胺酮显著增加膝下、膝前及背侧前扣带皮层血流且未被纳曲酮削弱;安慰剂预处理下膝前及膝下血流与急性主观效应及第1天抗抑郁反应相关,纳曲酮破坏了这些关联。
要点
- 氯胺酮增加膝下、膝前及背侧前扣带皮层血流,纳曲酮未削弱该效应。
- 安慰剂预处理下膝前血流与PSI妄想及知觉扭曲评分相关。
- 纳曲酮预处理破坏了膝下血流与第1天MADRS及QIDS-SR应答的关联。
核心结论
- 氯胺酮对重性抑郁障碍区域脑血流的影响受谷氨酸能、阿片能及GABA能系统复杂交互调节。
研究设计与样本
- 随机双盲交叉研究纳入26名18-50岁重性抑郁障碍成人,完成纳曲酮50 mg或安慰剂预处理后静脉氯胺酮0.5 mg/kg(40分钟)共两次治疗。
- 采用3-D伪连续动脉自旋标记MRI量化区域脑血流,并评估主观效应与临床结局。
主要发现
- 氯胺酮显著增加膝下、膝前及背侧前扣带皮层血流,且该效应未被纳曲酮削弱。
- 安慰剂预处理下,基线调整的输注期膝前相对血流与PSI妄想评分(r=0.56)及知觉扭曲评分(r=0.64)显著相关。
- 安慰剂预处理下,基线膝下血流(经全脑血流调整)与第1天MADRS(r=0.60)及QIDS-SR(r=0.67)抗抑郁应答显著相关。
- 纳曲酮预处理破坏了上述关联。
- 氯胺酮诱导的脑血流变化与MOR及mGluR5受体分布一致;纳曲酮交互作用与MOR、mGluR5及GABAAα5一致。
临床怎么用
- 膝前及膝下扣带皮层血流可能作为氯胺酮急性主观效应及早期抗抑郁应答的候选影像标志物。
- 阿片受体拮抗可能干扰氯胺酮效应相关的血流-症状关联,联合用药时需考虑。
局限性
- 样本量较小(26例),探索性受体空间相关分析需进一步验证。
- 未报告盲法评估及随访时长等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Accumulating evidence suggests that the opioid system may modulate ketamine's rapid antidepressant effects. The objective of this study was to test whether opioid system modulation via naltrexone alters ketamine's acute effects on regional cerebral blood flow (rCBF) in major depressive disorder (MDD), and whether these changes relate to symptom measures and map onto receptor density profiles. METHODS: In a randomized, double-blind, crossover study, 26 adults (18-50 years of age) with MDD completed two treatment sessions: oral naltrexone 50 mg or placebo, each followed by intravenous ketamine (0.5 mg/kg over 40 minutes) during 3-D pseudo-continuous arterial spin labeling MRI to quantify rCBF. Subjective effects were assessed with the Clinician-Administered Dissociative States Scale and the Psychotomimetic States Inventory (PSI), and clinical outcomes with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR). Exploratory analyses spatially correlated CBF maps with receptor density profiles (MOR, KOR, NMDA, mGluR5, GABAA, GABAAα5), correcting for spatial autocorrelation. RESULTS: Ketamine significantly increased CBF in subgenual, pregenual, and dorsal anterior cingulate cortices, and the effects were not attenuated by naltrexone. Under placebo pretreatment, baseline-adjusted infusion pregenual relative rCBF was significantly associated with acute subjective effects (PSI delusional score: r=0.56; PSI perceptual distortion score: r=0.64), and baseline subgenual rCBF (adjusted for global CBF) was significantly associated with day 1 antidepressant response (MADRS, r=0.60; QIDS-SR, r=0.67). Naltrexone pretreatment disrupted these associations. Ketamine-induced CBF changes aligned with MOR and mGluR5 receptor profiles; naltrexone's interaction aligned with MOR, mGluR5, and GABAAα5. CONCLUSIONS: The results suggest that ketamine's effects on CBF in MDD are influenced by complex interactions between glutamatergic, opioidergic, and GABAergic systems. These findings provide mechanistic insights with potential implications for optimizing ketamine-based treatments.
引用
- Jelen LA, O'Daly O, Zelaya FO, et al. Regional Blood Flow Signatures of Opioidergic Modulation of Ketamine in Major Depressive Disorder: A Randomized Crossover Study. Am J Psychiatry. 2026. PMID: 41922981. doi:10.1176/appi.ajp.20250903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。